
Moderna, Inc.
MRNAHealthcare|Biotechnology|US
$254.19
+12.73 (+5.27%)
Tangible Book / Share
$17.05
Cash / Share
$12.90
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05668741 A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | Cystic Fibrosis | P1P2 | Completed | 26 | Open-label | VX-522 mRNA therapy, IVA |